Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation. Inclusion Criteria: * Life expectancy at least 3 months * Diagnosis of a solid tumor which is unresectable in which no approved effective therapy exists or for subjects who are intolerable to such therapy. The initial enrollment will focus on non-small cell lung, gastric/esophageal adenocarcinoma, soft tissue sarcoma, transitional cell carcinoma, and pancreatic cancer including ampulla of Vater tumors * Adequate tumor sample * Adequate recovery (baseline or Grade 1) from recent therapy. At least 1 week must have elapsed from the time of a minor surgery, and at least 8 weeks for major surgery or radiation therapy Exclusion Criteria: * Subjects with known brain metastasis. * Subjects with signs or symptoms suggestive of brain metastasis are not eligible unless brain metastases are ruled out by CT or MRI Medical History and Concurrent Diseases: * History of thrombo-embolic disease within the last six months requiring therapeutic anticoagulation * Subjects with history of poor wound healing or non healing ulcers * Uncontrolled or significant cardiovascular disease Allergies and Adverse Drug Reactions: * History of allergy to brivanib its drug class, or related compounds Prohibited Treatments and/or Therapies: * Exposure to any investigational drug within 4 weeks of enrollment * Other concurrent chemotherapy, hormonal therapy, immunotherapy regimens or radiotherapy, standard or investigational. Subjects may continue to receive hormone replacement therapy * Prior exposure to brivanib